NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

ACRV

Acrivon Therapeutics Inc

May 21 • 04:00PM ET

1.15

Dollar change -0.10
Percentage change -8.00	%

Healthcare • Biotechnology • USA • NASD

Peers: BMRN VRTX REGN AMGN GILD BIIB EXEL INCY NBIX IONS

| Held by: VTI IWM VXF IBB IWN VTWO SCHA IWC CHNA SCHB

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.22	Insider Own	30.62%	Shs Outstand	31.35M	Perf Week	0.88%
Market Cap	36.05M	Forward P/E	-	EPS next Y	-2.31	Insider Trans	-19.03%	Shs Float	21.75M	Perf Month	-43.35%
Income	-83.75M	PEG	-	EPS next Q	-0.57	Inst Own	56.74%	Short Float	6.41%	Perf Quarter	-80.34%
Sales	0.00M	P/S	-	EPS this Y	7.47%	Inst Trans	-20.79%	Short Ratio	2.19	Perf Half Y	-83.48%
Book/sh	5.12	P/B	0.22	EPS next Y	-4.89%	ROA	-56.42%	Short Interest	1.39M	Perf Year	-87.06%
Cash/sh	4.77	P/C	0.24	EPS next 5Y	3.46%	ROE	-62.41%	52W Range	1.09 - 10.16	Perf YTD	-80.90%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-74.96%	ROI	-51.44%	52W High	-88.68%	Beta	1.69
Dividend TTM	-	Quick Ratio	11.17	Sales past 5Y	0.00%	Gross Margin	-	52W Low	5.50%	ATR (14)	0.19
Dividend Ex-Date	-	Current Ratio	11.17	EPS Y/Y TTM	22.94%	Oper. Margin	-	RSI (14)	33.60	Volatility	10.55% 10.90%
Employees	78	Debt/Eq	0.02	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.22	Target Price	10.71
Option/Short	No / Yes	LT Debt/Eq	0.02	EPS Q/Q	29.68%	Payout	-	Rel Volume	0.98	Prev Close	1.25
Sales Surprise	-	EPS Surprise	20.62%	Sales Q/Q	-	Earnings	May 14 AMC	Avg Volume	636.60K	Price	1.15
SMA20	-12.81%	SMA50	-50.76%	SMA200	-80.26%	Trades		Volume	624,408	Change	-8.00%

Date	Action	Analyst	Rating Change	Price Target Change
May-05-25	Resumed	Piper Sandler	Overweight	$6
Jan-31-25	Initiated	KeyBanc Capital Markets	Overweight
Sep-16-24	Upgrade	Ladenburg Thalmann	Neutral → Buy	$16
Apr-29-24	Downgrade	Ladenburg Thalmann	Buy → Neutral
Mar-01-24	Initiated	JMP Securities	Mkt Outperform	$14
Dec-15-23	Resumed	Jefferies	Buy	$17 → $12
Oct-05-23	Initiated	Maxim Group	Buy
Jun-02-23	Initiated	Oppenheimer	Outperform	$25
May-08-23	Initiated	BMO Capital Markets	Outperform	$25
Apr-27-23	Initiated	Ladenburg Thalmann	Buy	$22
Apr-20-23	Initiated	H.C. Wainwright	Buy	$24
Dec-12-22	Initiated	Piper Sandler	Overweight	$25
Dec-12-22	Initiated	Jefferies	Buy	$17
Dec-12-22	Initiated	Cowen	Outperform

Show Previous Ratings

May-17-25 12:30PM	Acrivon Therapeutics downgraded to Hold from Buy at JonesResearch (TipRanks)
May-14-25 04:10PM	Acrivon Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights (GlobeNewswire)
May-05-25 09:55AM	Here's Why Acrivon Therapeutics, Inc. (ACRV) Is a Great 'Buy the Bottom' Stock Now (Zacks)
Apr-28-25 12:23PM	Can Humana Beat Q1 Earnings Estimates on Growing Premiums? (Zacks) -5.49%
Apr-25-25 08:00AM	Acrivon Therapeutics to Reveal the Molecular Mechanisms Driving Strong Single-Agent Activity of ACR-2316, its AP3-Enabled Clinical Stage WEE1/PKMYT1 Inhibitor, at the AACR Annual Meeting 2025 (GlobeNewswire) -17.59%
11:00AM	Loading…
Apr-24-25 11:00AM	Universal Health to Report Q1 Earnings: Can it Surprise Wall Street? (Zacks)
Apr-23-25 01:41PM	HCA Healthcare to Report Q1 Earnings: Key Estimates to Note (Zacks)
01:28PM	Can Centene Beat Q1 Earnings Estimates on Growing Premiums? (Zacks)
Apr-22-25 11:19AM	Molina Healthcare to Report Q1 Earnings: Key Estimates to Watch (Zacks) +6.28%
Apr-14-25 09:35AM	Down -70.22% in 4 Weeks, Here's Why You Should You Buy the Dip in Acrivon Therapeutics, Inc. (ACRV) (Zacks) -7.41%
Apr-07-25 04:05PM	Acrivon Therapeutics Appoints World-Renowned Oncology Key Opinion Leader and Clinical Investigator Mansoor Raza Mirza, M.D., as Chief Medical Officer (GlobeNewswire) -7.95%
Mar-28-25 12:00PM	Acrivon Therapeutics, Inc. (ACRV) Upgraded to Buy: Here's What You Should Know (Zacks) -11.11%
09:35AM	Here's Why Acrivon Therapeutics, Inc. (ACRV) is Poised for a Turnaround After Losing -52.81% in 4 Weeks (Zacks)
Mar-27-25 05:44PM	Acrivon Therapeutics Provides Program Updates and Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Mar-19-25 08:00AM	Acrivon Therapeutics to Host Corporate R&D Event to Provide AP3 Platform Capabilities and Clinical ACR-368 and ACR-2316 Program Updates (GlobeNewswire)
08:16AM	Loading…
Feb-06-25 08:16AM	Acrivon Therapeutics announces FDA granted BDD for ACR-368 (TipRanks) -6.60%
04:54AM	FDA grants breakthrough designation for Acrivons endometrial cancer assay (Medical Device Network)
Feb-05-25 03:45PM	Acrivon Therapeutics (ACRV): AI-Powered Precision Oncology Gets FDA Breakthrough Status (Insider Monkey) +17.94%
08:00AM	Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Endometrial Cancer (GlobeNewswire)
Nov-13-24 07:00AM	Acrivon Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights (GlobeNewswire) -5.48%
Oct-17-24 08:00AM	Acrivon Therapeutics to Present Data Demonstrating Deployment of its AP3 Platform for Streamlined Drug Discovery and Clinical Development at Two Scientific Conferences - Human Proteome Organization World Congress and EORTC-NCI-AACR Symposium (GlobeNewswire)
Oct-16-24 04:00PM	Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-12-24 08:28AM	Acrivon Therapeutics Launches Phase 1 Cancer Trial, Advances Oncology Pipeline (TipRanks)
Oct-11-24 08:00AM	Acrivon Therapeutics Announces Initial Patient Dosing in Phase 1 Trial of ACR-2316, a Novel WEE1/PKMYT1 Inhibitor Designed Using AP3 for Superior Single-Agent Activity (GlobeNewswire)
Sep-14-24 03:10AM	Acrivon Therapeutics Reports Positive Endometrial Cancer Data from Ongoing ACR-368 Registrational Intent Phase 2 Study at ESMO, Advancement of ACR-2316 into Clinic Ahead of Timelines, and Progress on its AP3 Interactome for Proprietary Data Analysis (GlobeNewswire)
Sep-10-24 08:00AM	Acrivon Therapeutics to Present at the Cantor Global Healthcare Conference (GlobeNewswire) +8.61%
Sep-09-24 07:00AM	Acrivon Therapeutics to Host Virtual Investor Event to Review Positive Phase 2 Clinical Data of ACR-368 Presented at ESMO and Pipeline Progress, Including Clinical Candidate ACR-2316 (GlobeNewswire)
Aug-15-24 09:40AM	Are Medical Stocks Lagging Acrivon Therapeutics, Inc. (ACRV) This Year? (Zacks)
Aug-13-24 08:00AM	Acrivon Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights (GlobeNewswire)
Jun-21-24 09:40AM	Is Acrivon Therapeutics, Inc. (ACRV) Stock Outpacing Its Medical Peers This Year? (Zacks)
09:40AM	Loading…
Jun-05-24 09:40AM	Is Acrivon Therapeutics, Inc. (ACRV) Outperforming Other Medical Stocks This Year? (Zacks)
May-29-24 08:00AM	Acrivon Therapeutics to Present at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-28-24 09:47AM	Here's Why You Should Buy Acrivon Therapeutics (ACRV) Stock (Zacks)
May-20-24 09:40AM	Has Acrivon Therapeutics, Inc. (ACRV) Outpaced Other Medical Stocks This Year? (Zacks)
May-14-24 01:54PM	ACRV Stock Earnings: Acrivon Therapeutics Beats EPS for Q1 2024 (InvestorPlace)
08:00AM	Acrivon Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights (GlobeNewswire)
May-10-24 08:50AM	Is a Surprise Coming for Acrivon Therapeutics (ACRV) This Earnings Season? (Zacks) +7.74%
Apr-29-24 07:08AM	Ladenburg Thalmann Downgrades Acrivon Therapeutics to Neutral (MT Newswires) +18.20%
Apr-24-24 04:01PM	Acrivon Therapeutics Reports Initial Positive Clinical Data for ACR-368 and Pipeline Program Progress Today at Corporate R&D Event (GlobeNewswire) -10.84%
Apr-16-24 08:01PM	Acrivon Therapeutics to Host Corporate R&D Event Highlighting AP3 and Pipeline Progress, Including Ongoing Prospective Validation of ACR-368 OncoSignature with Initial Phase 2 Data for ACR-368, and Preclinical Progress for ACR-2316 (GlobeNewswire) +9.19%
Apr-10-24 08:00AM	Acrivon Therapeutics Presents Data at AACR Annual Meeting Highlighting the Capabilities of Acrivon Predictive Precision Proteomics (AP3) for the Discovery of ACR-2316, a Novel, Selective WEE1/PKMYT1 Inhibitor, and the Identification of Actionable Resistance Mechanisms to ACR-368 (GlobeNewswire) +8.00%
Apr-09-24 10:32AM	ACRV Stock Jumps 55% as Acrivon Therapeutics Gets $130 Million Boost (InvestorPlace) +62.77%
07:00AM	Acrivon Therapeutics Announces $130 Million Private Placement Financing (GlobeNewswire)
Mar-30-24 05:31AM	Acrivon Therapeutics Inc (ACRV) Reports Increased Annual Loss: A Detailed Look Against Analyst ... (GuruFocus.com)
Mar-28-24 12:52PM	ACRV Stock Earnings: Acrivon Therapeutics Misses EPS for Q4 2023 (InvestorPlace) +10.60%
08:00AM	Acrivon Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights (GlobeNewswire)
Mar-05-24 04:30PM	Acrivon Therapeutics to Present Data at AACR Annual Meeting Demonstrating Power of Acrivon Predictive Precision Proteomics (AP3) Platform and its Internally-Discovered, Potent WEE1/PKMYT1 Development Candidate, ACR-2316 (GlobeNewswire)
Mar-04-24 08:00AM	Acrivon Therapeutics Appoints Santhosh Palani, Ph.D., CFA, Experienced Board Member and Healthcare Investor, to its Board of Directors (GlobeNewswire) -11.40%
Feb-27-24 08:00AM	Acrivon Therapeutics to Participate in a Panel Discussion at the TD Cowen 44th Annual Health Care Conference (GlobeNewswire) +22.07%
Feb-08-24 08:00AM	Acrivon Therapeutics Appoints Seasoned Industry Executive Ivana Magov evi -Liebisch, Ph.D., J.D., to Board of Directors (GlobeNewswire)
Feb-06-24 08:00AM	Acrivon Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Jan-12-24 04:00PM	Acrivon Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -7.31%
Jan-04-24 08:00AM	Acrivon Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -6.63%
Jan-03-24 08:00AM	Acrivon Therapeutics Appoints Jean-Marie Cuillerot, M.D., as Chief Medical Officer (GlobeNewswire)
Nov-28-23 08:00AM	Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Ovarian Cancer (GlobeNewswire)
Nov-21-23 08:00AM	Acrivon Therapeutics to Present at the Piper Sandler Annual Healthcare Conference (GlobeNewswire) -9.02%
08:00AM	Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-09-23 08:01AM	Acrivon Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights (GlobeNewswire) -19.19%
Oct-16-23 08:00AM	Acrivon Therapeutics Presents Data Demonstrating Capabilities of its AP3 Platform and ACR-368 OncoSignature Assay for Patient Responder Identification at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
Sep-28-23 04:05PM	Acrivon Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-19-23 04:32PM	Acrivon Therapeutics to Highlight its ACR-368 OncoSignature Test, Used in Ongoing Phase 2 Study to Treat Patients Based on Predicted Sensitivity to Monotherapy with its CHK1/2 Inhibitor ACR-368, at the Upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
Sep-05-23 04:05PM	Acrivon Therapeutics Announces ACR-2316, a Novel Dual WEE1 and PKMYT1 Inhibitor Development Candidate, Designed Using Acrivons AP3 Platform to Achieve Potent Single Agent Activity, as Demonstrated in Preclinical Studies (GlobeNewswire)
Aug-30-23 08:00AM	Acrivon Therapeutics to Participate in Two Investor Conferences in September (GlobeNewswire)
Aug-17-23 04:00PM	Acrivon Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-11-23 07:00AM	Acrivon Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights (GlobeNewswire) +6.81%
Aug-08-23 12:38PM	Q2 2023 Akoya Biosciences Inc Earnings Call (Thomson Reuters StreetEvents)
Jul-20-23 08:00AM	Acrivon Therapeutics Announces the Appointment of Adam Levy, Ph.D., M.B.A., Experienced Biotech Investor Relations and Strategy Executive, to Senior Vice President and Head, Investor Relations and Corporate Affairs (GlobeNewswire)
Jun-29-23 04:49PM	7 Up-and-Coming Stocks to Buy for the Next Decade (InvestorPlace)
Jun-22-23 04:00PM	Acrivon Therapeutics Announces the Appointment of Seasoned Biopharma Executive Charles Baum, M.D., Ph.D., a Recognized Leader in Clinical Precision Oncology, to its Board of Directors (GlobeNewswire) +5.98%
Jun-02-23 08:00AM	Acrivon Therapeutics to Present at the Jefferies Healthcare Conference (GlobeNewswire)
May-09-23 10:43AM	Q1 2023 Akoya Biosciences Inc Earnings Call (Thomson Reuters StreetEvents) +6.77%
08:00AM	Acrivon Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights (GlobeNewswire)
08:00AM	Acrivon Therapeutics Announces FDA Grants Fast Track Designation for Development of ACR-368 in Platinum-Resistant Ovarian Cancer and Endometrial Cancer (GlobeNewswire)
May-07-23 08:17AM	We Think Acrivon Therapeutics (NASDAQ:ACRV) Can Afford To Drive Business Growth (Simply Wall St.)
Apr-25-23 08:00AM	Acrivon Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference (GlobeNewswire)
Apr-24-23 08:00AM	Acrivon Therapeutics to Host Virtual Investor Event on May 1, 2023 (GlobeNewswire)
Apr-18-23 08:00AM	Acrivon Therapeutics to Present at the Stifel 2023 Targeted Oncology Days Conference (GlobeNewswire)
Mar-28-23 08:00AM	Acrivon Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights (GlobeNewswire)
Mar-06-23 08:00AM	Acrivon Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare Conference (GlobeNewswire)
Feb-27-23 08:00AM	Acrivon Therapeutics to Participate on a Panel at Cowens 43rd Annual Health Care Conference (GlobeNewswire) +23.94%
Feb-15-23 05:40AM	Acrivon Therapeutics, Inc. (NASDAQ:ACRV) insider upped their holding earlier this year (Simply Wall St.)
Feb-14-23 10:15AM	2 Breakout Growth Stocks to Buy for the Long Haul (Motley Fool)
Jan-22-23 03:31PM	13 Cheap New Stocks To Buy (Insider Monkey)
Nov-14-22 10:16PM	Acrivon Therapeutics Announces Pricing of Initial Public Offering (GlobeNewswire)

Acrivon Therapeutics, Inc. develops drugs for clinical treatment. Its unique precision medicine platform is Acrivon Predictive Precision Proteomics (AP3). AP3 is used to generate proprietary OncoSignature companion diagnostics to identify patients who will benefit from the medicine. The company was founded by Peter Blume-Jensen and Kristina Masson in 2018 and is headquartered in Watertown, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
PERCEPTIVE ADVISORS LLC	10% Owner	Apr 30 '25	Sale	1.41	437,881	617,412	3,403,025	May 01 07:07 PM
PERCEPTIVE ADVISORS LLC	10% Owner	May 01 '25	Sale	1.34	298,886	400,507	3,104,139	May 01 07:07 PM
PERCEPTIVE ADVISORS LLC	10% Owner	Apr 25 '25	Sale	1.95	1,054,669	2,056,605	4,306,189	Apr 29 07:26 PM
PERCEPTIVE ADVISORS LLC	10% Owner	Apr 29 '25	Sale	1.41	250,000	352,500	3,840,906	Apr 29 07:26 PM
PERCEPTIVE ADVISORS LLC	10% Owner	Apr 28 '25	Sale	1.56	215,283	335,841	4,090,906	Apr 29 07:26 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ACRV

Acrivon Therapeutics Inc

Upgrade your FINVIZ experience